Sage remains tight-lipped on postpartum launch plans in wake of restructuring
In laying off 40% of its staff and trimming its pipeline early Thursday, Sage Therapeutics took the first step in a new direction as it aims to launch its postpartum depression drug Zurzuvae.
This news was expected after Sage alluded to such moves in the wake of this month’s FDA rejection of Zurzuvae in major depressive disorder (MDD), a decision that appeared to take company leaders and outside observers by surprise. But questions remain over how Sage will adjust its commercial strategy, how much the drug will cost and whether the company will continue to pursue an MDD approval.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
